Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $76.2 million.

  • Agios Pharmaceuticals' Cash & Equivalents fell 63.46% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year decrease of 63.46%. This contributed to the annual value of $76.2 million for FY2024, which is 13.56% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Cash & Equivalents of $76.2 million as of FY2024, which was down 13.56% from $88.2 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Cash & Equivalents ranged from a high of $203.1 million in FY2021 and a low of $76.2 million during FY2024.
  • Its 3-year average for Cash & Equivalents is $101.2 million, with a median of $88.2 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 59.39% in 2021, then crashed by 36.66% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Cash & Equivalents (Yearly) stood at $127.4 million in 2020, then spiked by 59.39% to $203.1 million in 2021, then crashed by 31.44% to $139.3 million in 2022, then slumped by 36.66% to $88.2 million in 2023, then decreased by 13.56% to $76.2 million in 2024.